Publications

Levy JA. Prospects for an AIDS vaccine: encourage innate immunity. AIDS (London, England). 2004. PMID: 15577631


Wang H, McCann FE, Gordan JD, Wu X, Raab M, Malik TH, Davis DM, Rudd CE. ADAP-SLP-76 binding differentially regulates supramolecular activation cluster (SMAC) formation relative to T cell-APC conjugation. The Journal of experimental medicine. 2004. PMID: 15477347


Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England journal of medicine. 2004. PMID: 15470214


Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer. 2004. PMID: 15468186


Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Molecular and cellular biology. 2004. PMID: 15367669


Allen GM, Shortall BP, Gemci T, Corcoran TE, Chigier NA. Computational simulations of airflow in an in vitro model of the pediatric upper airways. Journal of biomechanical engineering. 2004. PMID: 15648813


Allen J, Bergsland EK. Angiogenesis in colorectal cancer: therapeutic implications and future directions. Hematology/oncology clinics of North America. 2004. PMID: 15474337


Whisenant J, Venook A. Regional therapy of liver metastases. Current treatment options in oncology. 2004. PMID: 15341680


Tindall D, Horne FM, Hruszkewycz A, Mohla S, Shuman M, Wang Z, Kantoff P. Symposium on androgen action in prostate cancer. Cancer research. 2004. PMID: 15466216


Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nature reviews. Cancer. 2004. PMID: 15510162


Logan AC, Nightingale SJ, Haas DL, Cho GJ, Pepper KA, Kohn DB. Factors influencing the titer and infectivity of lentiviral vectors. Human gene therapy. 2004. PMID: 15585113


Gudmundsdottir K, Lord CJ, Witt E, Tutt AN, Ashworth A. DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. EMBO reports. 2004. PMID: 15359272


Amin A, Halabi S, Gelmann EP, Stadler W, Vogelzang N, Small E. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. Urologic oncology. 2004. PMID: 15464920


Rosenberg JE, Small EJ. Second-line chemotherapy for hormone-refractory prostate cancer: has the time come? Clinical prostate cancer. 2004. PMID: 15479496


Schmidt B, Ashlock B, Neipel F, Levy JA. Potential screening assay for undetectable viruses on the basis of their capacity to induce alpha interferon production. Journal of clinical microbiology. 2004. PMID: 15365027


Venook AP. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition. Journal of the National Comprehensive Cancer Network : JNCCN. 2004. PMID: 19780248


Venook AP. Key research issues in the management of hepatocellular carcinoma. Cancer chemotherapy and pharmacology. 2004. PMID: 15309518


Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004. PMID: 15289492